Payment overview · 2025
General Payments
$235.09
11 reported records · 5 companies
Healthcare provider profile · identity verified
Jeffrey A Johnson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HATTIESBURG, MS · NPI 1275647117
Verified facts
What the public records show
CMS Open Payments records show Jeffrey A Johnson, MD received $235.09 in general payments during 2025 across 11 reported records.
Merck Sharp & Dohme LLC accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $63.34 | 26.9% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $54.42 | 23.1% | 2 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $42.81 | 18.2% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.00 | 16.2% | 2 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $36.52 | 15.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $235.09 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $43.96 | 2 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $42.81 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $28.59 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| XACDURO Normalized: xacduro |
Drug | La Jolla Pharmaceutical Company | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $16.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 686 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 667 | 194 |
| Losartan Potassium | Losartan Potassium | 434 | 124 |
| Gabapentin | Gabapentin | 353 | 100 |
| Irbesartan | Irbesartan | 347 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 330 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 320 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 307 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 104 |
| Carvedilol | Carvedilol | 253 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 71 |
| Spironolactone | Spironolactone | 237 | 79 |
| Metformin Hcl | Metformin Hcl | 235 | 72 |
| Famotidine | Famotidine | 232 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 223 | 70 |
| Allopurinol | Allopurinol | 221 | 61 |
| Sertraline Hcl | Sertraline Hcl | 205 | 58 |
| Omeprazole | Omeprazole | 170 | 45 |
| Furosemide | Furosemide | 169 | 67 |
| Glipizide Er | Glipizide | 146 | 43 |
| Metformin Hcl Er | Metformin Hcl | 135 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 36 |
| Meloxicam | Meloxicam | 111 | 41 |
| Potassium Chloride | Potassium Chloride | 111 | 39 |
| Buspirone Hcl | Buspirone Hcl | 109 | 21 |
| Synthroid | Levothyroxine Sodium | 105 | 24 |
| Ozempic | Semaglutide | 103 | 25 |
| Trazodone Hcl | Trazodone Hcl | 103 | 32 |
| Azithromycin | Azithromycin | 96 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 42 |
| Mirtazapine | Mirtazapine | 93 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 32 |
| Ezetimibe | Ezetimibe | 90 | 28 |
| Trulicity | Dulaglutide | 89 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 88 | 88 |
| Valsartan | Valsartan | 86 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 24 |
| Jardiance | Empagliflozin | 81 | 17 |
| Tramadol Hcl | Tramadol Hcl | 79 | 23 |
| Finasteride | Finasteride | 78 | 21 |
| Telmisartan | Telmisartan | 77 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 22 |
| Lisinopril | Lisinopril | 75 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 72 | 52 |
| Eliquis | Apixaban | 70 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 23 |
| Montelukast Sodium | Montelukast Sodium | 68 | 25 |
| Mounjaro | Tirzepatide | 64 | 14 |
| Glimepiride | Glimepiride | 63 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 17 |
| Pregabalin | Pregabalin | 61 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 50 |
| Xarelto | Rivaroxaban | 55 | 11 |
| Alprazolam | Alprazolam | 53 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 24 |
| Fenofibrate | Fenofibrate | 46 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 45 | 14 |
| Linzess | Linaclotide | 43 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 39 |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Acarbose | Acarbose | 38 | 12 |
| Mupirocin | Mupirocin | 38 | 36 |
| Cefdinir | Cefdinir | 37 | 30 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | 13 |
| Donepezil Hcl | Donepezil Hcl | 35 | 14 |
| Azelastine Hcl | Azelastine Hcl | 34 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 17 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Prednisone | Prednisone | 29 | 13 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 15 |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Colchicine | Colchicine | 19 | 14 |
| Glipizide | Glipizide | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | 11 |
| Eplerenone | Eplerenone | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $235.09 · 11 records | Merck Sharp & Dohme LLC | APRETUDE, DOVATO, Fetroja, NUZYRA, PIFELTRO, XACDURO, ZERBAXA, ZEVTERA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error